Association of immunological response with the presence or absence of oral mood stabilizers in schizophrenia patients infected with COVID-19

Association of immunological response with the presence or absence of oral mood stabilizers in schizophrenia patients infected with COVID-19. - Association of immunological response with the presence or absence of oral mood stabilizers in schizophrenia patients infected with COVID-19.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050395

Enrollment

Registered

2023-03-01

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic phase schizophrenia infected with COVID-19 during hospitalization in a psychiatric hospital

Exclusion criteria

Exclusion criteria: Comorbidity of significant physical illness

Design outcomes

Primary

Measure	Time frame
IL-6 changes after COVID-19 infection	—

Countries

Japan

Contacts

Public ContactAkira Tanaka

Kurita hospital psychiatry

20hm122h@shinshu-u.ac.jp026-226-1311

Outcome results